Evidence map›Paper›PMID 25367878›Full record

SynthesisMolecular neurobiology2015

Identification and Evaluation of Serum MicroRNA-29 Family for Glioma Screening.

Junhua Wu, Liwen Li, Chunping Jiang

Abstract readEvaluation StudyMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Molecular neurobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. MicroRNAs as Biomarkers of Brain Tumor.Cancer management and research · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors.International journal of molecular sciences · 2021
    Review
  14. Review
  15. Article
  16. Review
  17. MicroRNA based theranostics for brain cancer: basic principles.Journal of experimental & clinical cancer research : CR · 2019
    Review
  18. A Systematic Review of miR-29 in Cancer.Molecular therapy oncolytics · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Junhua WuThe Affiliated Drum Tower Hospital, Medical School, Nanjing University, Hankou Road 22#, Nanjing, Jiangsu, 210093, China.
Liwen LiSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Chunping JiangThe Affiliated Drum Tower Hospital, Medical School, Nanjing University, Hankou Road 22#, Nanjing, Jiangsu, 210093, China. chunpingjiang@yeah.net.
Nanjing Drum Tower Hospital · CNNanjing University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is one of the most common primary central nervous system tumors with high mortality and poor 5-year survival rate. Current diagnostic methods for glioma were either invasive or expensive. MicroRNAs (miRNAs) are small non-coding RNAs which play an important part in the regulation of gene expression. Considering the fact that miRNAs are stable in serum, plasma, urine, and other body fluids, they show great promises to be convenient and non-invasive biomarkers for cancers. This study aimed at evaluating the availability of serum microRNA-29 (miR-29) family in screening of glioma. A meta-analysis was also performed to assess the predictive value of miR-29 family in multi-cancer screening. Serum samples were collected from 83 glioma patients at different stages and 69 healthy controls. RNA was extracted and the relative expression of serum miR-29 was acquired by qRT-PCR and calculated by Cycle threshold (Ct) with microRNA-24 as an internal control. In the meta-analysis, studies concerning the predictive value of miR-29 family in cancer were retrieved. The predictive value of serum miR-29 family for glioma was moderate (AUC = 0.74). But the predictive value of serum miR-29 family in high-graded glioma detection was sufficient (AUC = 0.81). Also, serum miR-29 family might not be applicable in early-stage glioma detection (AUC = 0.66). A high predictive value of miR-29 family in multi-cancer detection was observed from meta-analysis (AUC = 0.83). This study manifested that serum miR-29 family could be applied as a biomarker for high-graded glioma screening, but the sensitivity and specificity for low-graded glioma detection might not be sufficient. A meta-analysis concerning the predictive value of miR-29 family in multi-cancer detection concluded that miR-29 family might be a sufficient universal biomarker for cancer.

Indexed as

AdultAgedArea Under CurveBiomarkers, TumorBrain NeoplasmsCase-Control StudiesEarly Detection of CancerFemaleGlioblastomaGliomaHumansMaleMicroRNAsMiddle AgedNeoplasm GradingNeoplasm StagingBiomarkers, TumorMicroRNAsMIRN29a microRNA, humanGliomaMeta-analysisMicroRNA-29 familyScreeningSerum

Identifiers

PMID25367878
OpenAlexW1996402225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.